Head of BioTx and Large Molecule Biomarker Bioanalysis
Pfizer, Inc.
Dr Hendrik Neubert serves as a Senior Director in Pfizer’s BioMedicine Design department where he leads a translational biomeasures and biomarkers group. He is based in Andover/Cambridge (Massachusetts) working across several disease areas. He and his team develop innovative biomarker assays based on mass spectrometry and flow cytometry to enable mechanistic PK/PD and PBPK modeling with critical experimental data. Hendrik and his team have been very influential in the area of immunoaffinity mass spectrometry of protein biomarkers. One of the key achievements has been to robustly position this technology in early clinical trials. Hendrik joined Pfizer in the United Kingdom in 2004 as a Manager in Clinical Pharmacology working in clinical proteomics and targeted MS for protein biomarkers, biologics and immunogenicity. Prior to joining Pfizer, Hendrik held a post-doc position at King’s College London and studied both at King’s College and ETH Zurich.